Nootropics, Herbal Medicine & Cognitive Neuroscience · · 21 min read · By

Dihexa vs Ginkgo Biloba for Memory, Focus & Brain Fog: The 2026 UK Review

Ginkgo biloba for memory, focus and brain fog - 2026 UK evidence review illustration showing a fan-shaped ginkgo leaf, a brain and cerebral blood flow

Ginkgo biloba is the most famous “memory herb” on earth — a living fossil sold in every pharmacy and searched for by students before exams, professionals fighting the 3 pm slump and executives worried about a slipping memory. It is also one of the most rigorously tested supplements in existence, which is exactly why we can be honest about it: in healthy people, the best meta-analysis found essentially no effect on memory, attention or focus, and two huge trials proved it does not prevent dementia. Where a real, modest signal survives is in brains that are already impaired. Into the same search results lands Dihexa, a synaptogenic HGF/c-Met peptide with a far bolder story and a far thinner evidence base. This 2026 UK review sets the two side by side — and explains why the honest verdict for a healthy high performer is that neither is a shortcut.

Not medical advice. Dihexa (PNB-0408) is an unscheduled research chemical, not an approved treatment for brain fog or any condition. Ginkgo biloba is sold in the UK as a traditional herbal medicine and food supplement; this page is general information, not a recommendation to take it, and it does not sell ginkgo or Dihexa. Ginkgo can interact with blood-thinning and other medicines — check with a pharmacist or GP before use. Nothing here is medical advice. If you have persistent brain fog or memory problems, see your GP to rule out treatable causes. Read the full legal disclaimer.

Key Findings: Ginkgo Biloba for Memory, Focus & Brain Fog vs Dihexa

  • It does little for a healthy brain: A 2012 meta-analysis of healthy adults found near-zero, non-significant effects on memory, attention and executive function — the opposite of what the marketing implies.
  • It does not prevent dementia: The GEM trial (JAMA, 2008) and the GuidAge trial (Lancet Neurology, 2012), together ~5,800 older adults, both found no reduction in dementia or Alzheimer’s.
  • Its real signal is in impaired brains: Meta-analyses of the standardised EGb 761 extract at 240 mg/day show modest gains in cognition and daily function in established mild dementia — a narrow, genuine use.
  • Mechanism is vascular and antioxidant: Flavonoid glycosides (antioxidants) and terpene lactones (ginkgolides + bilobalide) that improve cerebral microcirculation and block platelet-activating factor — which is also why it thins the blood.
  • The safety catch is bleeding: Ginkgo can raise bleeding risk with warfarin, antiplatelets and before surgery — stop it two weeks pre-op and avoid in pregnancy.
  • Dosing is slow and standardised: 120–240 mg/day of a standardised extract (24% flavone glycosides, 6% terpene lactones), judged over 8–12 weeks, not hours — unlike the caffeine hit people expect.
  • Dihexa is the opposite trade-off: A bold synaptogenic mechanism but no completed human trial for cognition, a pro-proliferative c-Met concern, and a drug relative — fosgonimeton — that failed Phase 3.
  • Bottom line: Ginkgo is a real medicine for the wrong problem if you are healthy; Dihexa is an unproven one. For a sharper mind, the evidence-based basics beat both.

Why Everyone Reaches for Ginkgo — and the 2026 Supplement Boom

Ginkgo biloba has a head start no other nootropic can match: reputation. The tree is a living fossil, essentially unchanged for 200 million years, and its fan-shaped leaf has been used in traditional Chinese medicine for centuries. By the time modern supplements arrived, “ginkgo for memory” was already folk knowledge, and it remains, alongside lion’s mane and omega-3, one of the first things people buy when they feel their focus slipping. Type “best supplement for memory” into a search bar and ginkgo is never far away.

That demand is booming. The global brain-health supplement market was worth roughly $14 billion in 2026 and is forecast to more than double within a decade, and the UK is a hotspot: survey data suggest around 31% of British adults aged 18–35 bought a nootropic or adaptogenic supplement in a single recent year, reaching for compounds like bacopa, rhodiola, L-theanine and ginkgo to manage cognitive fatigue and stay productive. The rise of hybrid work, always-on messaging and exam pressure has turned “how do I think more clearly?” into a mass-market question — and ginkgo, cheap and familiar, is a default answer.

But popularity is not evidence, and ginkgo is unusual precisely because we can check the folklore against decades of high-quality trials. When we do, the story is far more nuanced than the packaging suggests — and understanding it tells you almost everything you need to know about why chasing a peptide like Dihexa for the same goal is even less justified.

What Ginkgo Biloba Actually Is: EGb 761, Flavonoids & Ginkgolides

“Ginkgo” on a label can mean very different things, and the distinction matters. The credible research almost all uses a specific, patented, standardised leaf extract called EGb 761, manufactured to a fixed composition: about 24% flavonoid (flavone) glycosides and 6% terpene lactones. Those two families are the active ingredients. The flavonoids — quercetin, kaempferol and their relatives — are antioxidants that scavenge free radicals. The terpene lactones are the ginkgolides (A, B and C) and bilobalide, molecules almost unique to ginkgo.

A cheap, unstandardised “ginkgo leaf 5000 mg” capsule may contain a fraction of the active compounds of a standardised EGb 761 dose, which is one reason casual users often feel nothing at all. It also means much of the internet’s “ginkgo did nothing for me” and “ginkgo changed my life” noise is comparing different products entirely. If you are going to judge ginkgo, judge the standardised extract at a proper dose — the version that was actually tested.

How Ginkgo Works in the Brain: Blood Flow, Antioxidants & Platelets

Ginkgo’s proposed mechanism is vascular and protective rather than stimulant. Three strands are usually cited. First, improved cerebral microcirculation: ginkgo appears to modestly increase blood flow in small vessels, which could help a brain whose supply is compromised by ageing or vascular disease. Second, antioxidant and neuroprotective activity: the flavonoids mop up reactive oxygen species and the terpenes appear to protect neurons and mitochondria against oxidative and ischaemic stress. Third, and importantly for safety, the ginkgolides are platelet-activating factor (PAF) antagonists — they interfere with a signal that makes platelets clump, giving ginkgo a mild anti-clotting, blood-thinning effect.

Notice what this mechanism is not. It is not a fast neurotransmitter push like caffeine, and it is not obviously a synapse-building growth signal like the one Dihexa targets. It is a slow, background, vascular-and-antioxidant story — the kind of mechanism you would expect to matter most in a brain that is already struggling with blood supply or oxidative damage, and to matter least in a healthy 25-year-old’s cortex. That single prediction turns out to match the trial data almost exactly.

Why this matters for the Dihexa comparison. Ginkgo and Dihexa sit at opposite ends of a spectrum. Ginkgo has a plausible, modest, well-characterised mechanism and a large human evidence base that limits its promise. Dihexa has a dramatic mechanism on paper — plasticity and synaptogenesis — but almost no human evidence to say whether it does anything at all. Knowing what a compound does in a dish is not the same as knowing what it does to you.

The Decisive Evidence: Ginkgo Does Almost Nothing for a Healthy Brain

This is the section that matters most for the people this site’s readers usually are: students, founders, executives and high performers with fundamentally healthy brains who want an edge. And the evidence here is unusually clean. A 2012 meta-analysis by Laws and colleagues pooled randomised, placebo-controlled trials of ginkgo in healthy adults, covering memory (13 studies, 1,132 people), executive function (7 studies, 534 people) and attention (8 studies, 910 people). The result was as close to a flat line as psychopharmacology produces: effect sizes of roughly −0.04 for memory, −0.05 for executive function and −0.08 for attention — all tiny, all non-significant, and all pointing, if anything, very slightly the wrong way. As the authors put it, ginkgo had “no ascertainable positive effects” on cognition in healthy people.

More recent work has not overturned this. A 2025 network meta-analysis of natural extracts for cognition in healthy adults again failed to find ginkgo to be a reliable enhancer. The pattern is consistent across two decades: whatever ginkgo does, it does not measurably sharpen an already-healthy memory, attention span or executive function. For the exam-cramming student or the founder chasing deep focus, that is the headline — and it is the same headline this site keeps writing about “smart” compounds, from methylene blue to the peptides.

The Prevention Question: GEM & GuidAge Said No

If ginkgo cannot sharpen a healthy brain today, could it at least protect one for the future? This was tested about as seriously as any supplement has ever been, in two large, long, government- and industry-funded randomised trials.

The American Ginkgo Evaluation of Memory (GEM) study, published in JAMA in 2008, randomised around 3,000 older adults (normal cognition or mild cognitive impairment) to 120 mg of EGb 761 twice daily or placebo and followed them for a median of about six years. Ginkgo had no effect on the rate of progression to all-cause dementia or Alzheimer’s disease. The French GuidAge trial, published in Lancet Neurology in 2012, enrolled about 2,850 adults aged 70+ who had spontaneously reported memory complaints to their GP, gave them long-term standardised ginkgo, and again found no reduction in progression to Alzheimer’s.

Two independent trials, nearly 5,800 people between them, years of follow-up, a proper standardised extract — and both came back negative for prevention. That is a strong, consistent result, and it is why mainstream bodies do not recommend ginkgo to prevent dementia. It is also a useful yardstick: this is what a genuinely well-tested cognitive supplement looks like, and it is a standard of evidence Dihexa comes nowhere near.

Where Ginkgo Does Work: Established Mild Dementia

The honest flip side — and the reason ginkgo is a registered medicine in several European countries rather than a discredited fad — is that in people who already have dementia, the picture changes. Multiple meta-analyses of randomised, placebo-controlled trials of EGb 761 at 240 mg a day report modest but statistically significant benefits in mild dementia: small improvements in cognition, in activities of daily living, and in global clinical impression, with a side-effect rate no different from placebo. A 2024–2025 meta-analysis of patient subgroups concluded that EGb 761 is “safe and effective in the treatment of mild dementia,” and 2025–2026 pooled analyses, including in patients with dementia and prior stroke, point the same way.

The effect is real but small, and it applies to an impaired brain, not a healthy one — exactly what the vascular, antioxidant, blood-flow mechanism predicts. This is the crucial nuance the marketing flattens: ginkgo is a plausible adjunct in early dementia, not a focus pill for the well. If you or a relative has a diagnosis of mild dementia, ginkgo at a standardised 240 mg is a reasonable thing to discuss with a doctor. If you are a healthy 40-year-old who just wants to feel sharper, the same product has repeatedly failed to help people like you in trials.

Ginkgo & Everyday Brain Fog: The Missing Evidence

What about ordinary brain fog — the foggy, unfocused, word-finding-trouble state that sends most people searching in the first place? Here the honest answer is that there is essentially no good trial evidence for ginkgo. Brain fog is not a disease; it is a symptom, and its common drivers are eminently fixable: poor sleep, chronic stress and burnout, nutrient shortfalls like B12, iron, vitamin D or magnesium, an underactive thyroid, hormonal shifts such as menopause, medication side effects, and conditions like long COVID.

Ginkgo does not address any of those root causes. A brain fogged by iron deficiency needs iron; one fogged by sleep debt needs sleep; one fogged by an antidepressant or antihistamine needs a medication review. Layering a mild vascular herb on top of an untreated cause is, at best, a distraction. This is the recurring lesson of the whole brain-fog series, and it applies to ginkgo and Dihexa alike: diagnose the cause first. A supplement chosen before the cause is known is a guess.

Ginkgo Dosage, Timeline & What to Look For

If, after all that, ginkgo is still something you or a relative want to try — for early dementia under medical guidance, or simply because you have decided the modest evidence is enough — the details matter:

  • Use a standardised extract. Look for “EGb 761” or an extract standardised to ~24% flavone glycosides and ~6% terpene lactones. Ignore the headline “5000 mg leaf” numbers; the standardisation is what counts.
  • Dose. The trials use 120–240 mg a day; 240 mg is the dementia dose. More is not better and adds bleeding risk.
  • Timeline. Any effect builds slowly — give it 8–12 weeks before judging. Ginkgo is not a same-day focus hit; if you feel a buzz in an hour, that is expectation, not pharmacology.
  • Consistency and quality. Herbal products vary widely; choose a reputable brand, ideally one carrying a UK Traditional Herbal Registration (THR) mark, which at least guarantees quality and dosing (not efficacy).

Safety, Side Effects & the Bleeding Risk You Must Not Ignore

For most healthy adults, standardised ginkgo is well tolerated in the short term, with only occasional mild headache, gastrointestinal upset or dizziness — and in the dementia trials its side-effect rate matched placebo. But there is one concern that genuinely matters, and it flows directly from the PAF-antagonist mechanism above: bleeding.

Because ginkgo mildly thins the blood, the US National Center for Complementary and Integrative Health and UK pharmacists advise real caution when it is combined with anticoagulants such as warfarin or DOACs, with antiplatelet drugs such as aspirin or clopidogrel, or with other supplements that affect clotting. The standard advice is to stop ginkgo at least two weeks before any surgery or dental procedure, and to avoid it entirely in pregnancy and breastfeeding. It can also interact with some antidepressants, anticonvulsants and other medicines. One more, separate warning: raw or roasted ginkgo seeds (not the leaf extract) contain a genuine neurotoxin and can cause seizures — they are a different substance from the supplement entirely.

The practical rule is simple: if you take any regular medication, especially anything affecting the blood, or you are pregnant, planning surgery or breastfeeding, talk to a pharmacist or GP before starting ginkgo. It is a real medicine with real interactions, not an inert “natural” freebie.

Where Dihexa Enters: A Bolder Claim on a Thinner Base

Against that backdrop, where does Dihexa (PNB-0408) sit? It is a small peptide derived from angiotensin IV, developed as a positive modulator of the HGF/c-Met pathway. Hepatocyte growth factor (HGF), acting on its c-Met receptor, drives synaptogenesis — the formation of new synaptic connections — and MET signalling stays active in the adult hippocampus and prefrontal cortex. In the original Benoist 2014 work, Dihexa improved learning in rodents in an HGF/Met-dependent way, and early laboratory reports described it as strikingly potent at building dendritic spines. On paper, it is a far more ambitious idea than a blood-flow herb: not tuning the vasculature, but rewiring the network.

The problem is the evidence gap. Ginkgo’s modest claims rest on tens of thousands of humans across randomised trials; that is why we can say precisely where it works and where it does not. Dihexa’s bold claims rest almost entirely on animal and cell data. There is no completed, published human efficacy trial of Dihexa for memory, focus, brain fog or any cognitive outcome. We do not have a Laws-style meta-analysis showing Dihexa sharpens healthy cognition, nor a GEM-style trial showing it prevents decline, because those trials have not been done. A dramatic mechanism with no human read-out is a hypothesis, not a benefit — a distinction the research and studies page makes at length.

The Fosgonimeton Warning: When the Pathway Was Tested Properly

There is one place the HGF/c-Met idea has been tested at the highest level — and the result is sobering. Fosgonimeton (ATH-1017), developed by Athira Pharma, is a purpose-built small-molecule positive modulator of the same HGF/MET system Dihexa targets. It reached a full Phase 3 Alzheimer’s trial, LIFT-AD, and in 2024 it missed its primary endpoint. A professionally manufactured drug, hitting the exact pathway, in a rigorous trial, failed to deliver the hoped-for cognitive benefit.

That does not prove the pathway is worthless — trials fail for many reasons — but it is a pointed caution for anyone assuming an unlicensed peptide bought online will outperform both a Phase 3 pharmaceutical and a herb with decades of trials behind it. Weigh ginkgo, whose modest claims keep passing human tests, against Dihexa, whose bold claims are untested in humans and whose closest drug relative has already failed, and the asymmetry is hard to miss.

Ginkgo vs Dihexa: The Honest Head-to-Head

Put simply, ginkgo and Dihexa fail the healthy high performer in opposite ways. Ginkgo is a real, safe-ish, well-tested medicine aimed at the wrong target for a healthy brain: it does little for you today and will not protect you tomorrow, though it has a narrow, legitimate role in early dementia. Dihexa is an unproven research chemical aimed at an exciting target with no human evidence that it hits it, and with a safety flag ginkgo does not carry.

On safety, ginkgo’s main risk — bleeding — is known, predictable and manageable. Dihexa’s central concern is different in kind: because c-Met activation is pro-proliferative, and c-Met is implicated in numerous cancers, a compound designed to switch that pathway on carries a theoretical tumour-growth concern that has never been characterised in humans. Ginkgo you can research, dose and stop before surgery. Dihexa you are dosing blind. For the specific goal of a sharper, clearer mind in a healthy person, that makes ginkgo the safer disappointment and Dihexa the riskier gamble — and it makes the boring fundamentals better than either.

What Actually Sharpens a Healthy Mind

If ginkgo does not enhance a healthy brain and Dihexa is unproven, what does move the needle? The unglamorous, best-evidenced levers — the ones this site keeps coming back to:

  • Sleep, protected and prioritised. Nothing on a supplement shelf rivals consistent, sufficient sleep for memory, focus and mood — see insomnia & sleep deprivation and sleep & memory consolidation.
  • Exercise. Aerobic exercise is the most reliable way to raise BDNF and support the ageing brain — the very plasticity currency Dihexa only hopes to touch.
  • Fix deficiencies and treat conditions. Address B12, iron, vitamin D and thyroid issues; a GP work-up beats guessing.
  • Use the best-evidenced basics. The caffeine + L-theanine stack, omega-3 and creatine have better healthy-adult evidence than ginkgo — see the best nootropics for studying guide.
  • Manage stress and load. Chronic stress and burnout fog the mind more than most people admit; recovery is a cognitive intervention.
  • Skip the unproven peptide. Layering an unlicensed research chemical on top of unfixed fundamentals adds risk without evidence — the theme of the Dihexa vs nootropics comparison and the stacking guide.

The Bottom Line

Ginkgo biloba is the rare supplement famous enough, and tested enough, that we can give a clear verdict: for a healthy student, professional or executive, it does almost nothing for memory, focus or brain fog, and it will not prevent dementia — but at a standardised 240 mg it has a genuine, modest role in established mild dementia, provided the bleeding risk is respected. That is a useful, narrow truth, and it is more than most nootropics can claim. Dihexa offers a bolder promise on a far thinner foundation: an exciting synaptogenic mechanism, no completed human trials for cognition, a pro-proliferative c-Met flag, and a drug relative that failed Phase 3. If your goal is a sharper mind, the ranking is not close: fix your sleep, movement, nutrition and stress first; consider ginkgo only for the specific, impaired-brain use it is actually good for; and keep the unlicensed peptide last. As ever on this site, the well-studied path wins.

Frequently Asked Questions

Does ginkgo biloba actually improve memory and focus?

For a healthy person, no. The decisive 2012 meta-analysis of healthy adults found near-zero, non-significant effects on memory, attention and executive function, and the large GEM and GuidAge trials found it did not prevent dementia. A modest, genuine benefit appears only in people who already have mild dementia, where EGb 761 at 240 mg/day helps a little.

Can ginkgo biloba help brain fog?

There is no good trial evidence that ginkgo clears everyday brain fog. Fog is usually a symptom of sleep debt, stress, nutrient deficiencies, hormones or medication — fixable causes ginkgo does not address. The higher-yield move is to find and treat the cause rather than reach for a herb that failed to help healthy brains in controlled trials.

What is the correct ginkgo biloba dosage?

Use a standardised extract (EGb 761 or ~24% flavone glycosides / 6% terpene lactones) at 120–240 mg a day; 240 mg is the dementia-trial dose. Effects build over 8–12 weeks, not hours. Cheap unstandardised “ginkgo leaf” capsules may contain little active extract, and going above 240 mg adds bleeding risk without added benefit.

Is ginkgo biloba safe? What are the side effects?

Short-term standardised ginkgo is usually well tolerated (occasional mild headache, stomach upset or dizziness). The key concern is bleeding: ginkgo mildly thins the blood, so avoid it with warfarin, other anticoagulants and antiplatelets, stop it two weeks before surgery, and avoid it in pregnancy and breastfeeding. Check with a pharmacist or GP if you take any regular medication.

Ginkgo biloba vs Dihexa — which is better for cognition?

Ginkgo is a licensed traditional herbal medicine with decades of human trials, which is why we can say it does little for a healthy brain and only modestly helps an impaired one. Dihexa is an unlicensed research chemical with no completed human efficacy trial, a pro-proliferative c-Met flag, and a drug relative — fosgonimeton — that failed Phase 3. For a healthy high performer neither is a shortcut, but ginkgo at least has the safety and evidence base the peptide lacks.

How does ginkgo biloba work in the brain?

Its two active families are flavonoid glycosides (antioxidants) and terpene lactones (ginkgolides and bilobalide). The ginkgolides block platelet-activating factor, giving ginkgo a mild blood-flow and anti-clotting effect, and the extract is thought to improve cerebral microcirculation and protect neurons from oxidative stress. This vascular, antioxidant mechanism fits the finding that ginkgo helps impaired brains more than healthy ones.

External Authoritative Sources Cited

Editorial statement: This article is part of a rolling 2026 clinical-context review series examining where Dihexa sits in the evidence hierarchy for specific concerns. We are not clinicians, and we do not sell ginkgo, Dihexa or any supplement. This page is for education and is not medical advice. See the About page for our editorial approach and the disclaimer for legal scope. If brain fog or memory problems are affecting your daily life, please speak to your GP.